Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series [PDF]
Annals of Saudi MedicineBACKGROUND: Apixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE).
Hakeam A. Hakeam +3 more
doaj +2 more sources
Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability [PDF]
JHLT OpenApixaban is increasingly replacing vitamin K antagonists (VKAs) during HeartMate 3 (HM3) left ventricular assist device support, but its pharmacodynamics in this setting remain poorly understood.
Charlotte J. Van Edom, MD +9 more
doaj +2 more sources
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients [PDF]
New England Journal of Medicine, 2011 The efficacy and safety of prolonging prophylaxis for venous thromboembolism in medically ill patients beyond hospital discharge remain uncertain. We hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-term ...
+8 more
exaly +5 more sources
Pharmacokinetics and Biologic Activity of Apixaban in Healthy Dogs
Frontiers in Veterinary Science, 2021 Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans.
Noelle D. Herrera +5 more
doaj +1 more source
Hospital Pharmacy, 2013 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J +2 more
openaire +3 more sources
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. [PDF]
PLoS ONE, 2018 Prior real-world studies have shown that apixaban is associated with a reduced risk of stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin.
Xiaoyan Li +11 more
doaj +1 more source
Scientific Reports, 2021 In some clinical situations, measurements of anticoagulant effect of apixaban may be needed. We investigated the inter- and intra-individual apixaban variability in patients with atrial fibrillation and correlated these results with clinical outcome.
Alenka Mavri +7 more
doaj +1 more source
Idiopathic Bilateral Internal Jugular Vein Thrombosis Diagnosed by Point-of-Care Ultrasound [PDF]
, 2020 Internal jugular vein (IJV) thrombosis is an unusual condition, especially when it develops bilaterally. This is a case of bilateral IJV thrombosis in a 77-year old female who presented to the emergency department with neck and arm swelling after ...
Aquino-Jose, Victor M. +2 more
core +2 more sources
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. [PDF]
PLoS ONE, 2012 BACKGROUND: Apixaban was shown to be superior to adjusted-dose warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke, and associated with reduced rates of ...
Soyon Lee +3 more
doaj +1 more source